Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab versus second-dose IVIG for IVIG-unresponsive Kawasaki disease
ChiCTR1900027954Phase 3Not yet recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Kawasaki disease (KD) comparing IVIG group with Infliximab group (2 arms). Primary endpoints: Febrile duration after treatment, Defervescence rate within 48 hours after treatment and 2 more. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
infliximabimmune globulin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on ChiCTR1900027954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027954.